Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Microneedle Patch Hepatitis B Vaccine in Healthy Adults
NCT06800131Phase 1Not yet recruiting
- Sponsor
- International Vaccine Institute
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, open-label trial of QMV-24KRP in hepatitis B (HBV) (2 arms), sponsored by International Vaccine Institute. Primary endpoint: Safety and tolerability of investigational product (QMV-24KRP) at 52 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
QMV-24KRP
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06800131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800131.